Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
In this application note, we demonstrate how the C
The Nobel Prize in Physiology or Medicine awarded
In today’s rapidly evolving bioprocessing landsc
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Mi
The leader of the European Union’s drugs office Guido Rasi said on Monday an underlying authorisation for U.S. pharmaceutical organization Gilead’s remdesivir as a COVID-19 treatment could be conceded in coming days.
The European Medicines Agency (EMA) has just suggested the caring utilization of remdesivir, which permits a medication to be directed to patients even before it has been completely approved.
“It may be that a contingent market authorisation can be given in the coming days,” Rasi told a meeting in the EU Parliament in Brussels.
Aside from remdesivir, Rasi said other potential medications against COVID-19 that might be accessible quick are those dependent on monoclonal antibodies, which can “kill” the new coronavirus (SARS-CoV-2) that causes the ailment COVID-19.
